Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Allosteric effects govern nuclear receptor action: DNA appears as a player.

Gronemeyer H, Bourguet W.

Sci Signal. 2009 Jun 2;2(73):pe34. doi: 10.1126/scisignal.273pe34.

PMID:
19491383
2.

Estrogen-like endocrine disrupting chemicals affecting puberty in humans--a review.

Roy JR, Chakraborty S, Chakraborty TR.

Med Sci Monit. 2009 Jun;15(6):RA137-45. Review.

PMID:
19478717
3.

Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit.

Mohler ML, Bohl CE, Jones A, Coss CC, Narayanan R, He Y, Hwang DJ, Dalton JT, Miller DD.

J Med Chem. 2009 Jun 25;52(12):3597-617. doi: 10.1021/jm900280m. Review. No abstract available.

PMID:
19432422
4.

Peroxisome proliferator-activated receptor gamma in bladder cancer: a promising therapeutic target.

Mansure JJ, Nassim R, Kassouf W.

Cancer Biol Ther. 2009 Apr;8(7):6-15. Review.

PMID:
19417560
5.

DNA binding site sequence directs glucocorticoid receptor structure and activity.

Meijsing SH, Pufall MA, So AY, Bates DL, Chen L, Yamamoto KR.

Science. 2009 Apr 17;324(5925):407-10. doi: 10.1126/science.1164265.

6.

Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes.

Baxter JD, Webb P.

Nat Rev Drug Discov. 2009 Apr;8(4):308-20. doi: 10.1038/nrd2830. Review.

PMID:
19337272
7.

Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease.

Robinson E, Grieve DJ.

Pharmacol Ther. 2009 Jun;122(3):246-63. doi: 10.1016/j.pharmthera.2009.03.003. Epub 2009 Mar 24. Review.

PMID:
19318113
8.

The structural basis of gas-responsive transcription by the human nuclear hormone receptor REV-ERBbeta.

Pardee KI, Xu X, Reinking J, Schuetz A, Dong A, Liu S, Zhang R, Tiefenbach J, Lajoie G, Plotnikov AN, Botchkarev A, Krause HM, Edwards A.

PLoS Biol. 2009 Feb 24;7(2):e43. doi: 10.1371/journal.pbio.1000043.

9.

Structural basis for the activation of PPARgamma by oxidized fatty acids.

Itoh T, Fairall L, Amin K, Inaba Y, Szanto A, Balint BL, Nagy L, Yamamoto K, Schwabe JW.

Nat Struct Mol Biol. 2008 Sep;15(9):924-31.

10.

Deconstructing estradiol: removal of B-ring generates compounds which are potent and subtype-selective estrogen receptor agonists.

Asim M, El-Salfiti M, Qian Y, Choueiri C, Salari S, Cheng J, Shadnia H, Bal M, Christine Pratt MA, Carlson KE, Katzenellenbogen JA, Wright JS, Durst T.

Bioorg Med Chem Lett. 2009 Feb 15;19(4):1250-3. doi: 10.1016/j.bmcl.2008.12.080. Epub 2008 Dec 24. Erratum in: Bioorg Med Chem Lett. 2009 May 1;19(9):2605. Asim, Mohammud [corrected to Asim, Muhammad]. Bioorg Med Chem Lett.2010 Nov 15;20(22):6861-2.

PMID:
19167882
11.

Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention.

Ondrey F.

Clin Cancer Res. 2009 Jan 1;15(1):2-8. doi: 10.1158/1078-0432.CCR-08-0326. Review.

12.

Nuclear receptors: one big family.

McEwan IJ.

Methods Mol Biol. 2009;505:3-18. doi: 10.1007/978-1-60327-575-0_1. Review.

PMID:
19117136
13.

Liver X receptor modulators: effects on lipid metabolism and potential use in the treatment of atherosclerosis.

FiƩvet C, Staels B.

Biochem Pharmacol. 2009 Apr 15;77(8):1316-27. doi: 10.1016/j.bcp.2008.11.026. Epub 2008 Dec 3. Review.

PMID:
19101522
14.

Selective androgen receptor modulators in preclinical and clinical development.

Narayanan R, Mohler ML, Bohl CE, Miller DD, Dalton JT.

Nucl Recept Signal. 2008;6:e010. doi: 10.1621/nrs.06010. Epub 2008 Nov 26. Review.

15.

Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA.

Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, Burris TP, Rastinejad F.

Nature. 2008 Nov 20;456(7220):350-6. doi: 10.1038/nature07413.

16.

Fenofibrate: treatment of hyperlipidemia and beyond.

Rosenson RS.

Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1319-30. doi: 10.1586/14779072.6.10.1319. Review.

PMID:
19018684
17.

The first X-ray crystal structure of the glucocorticoid receptor bound to a non-steroidal agonist.

Madauss KP, Bledsoe RK, Mclay I, Stewart EL, Uings IJ, Weingarten G, Williams SP.

Bioorg Med Chem Lett. 2008 Dec 1;18(23):6097-9. doi: 10.1016/j.bmcl.2008.10.021. Epub 2008 Oct 8.

PMID:
18952422
18.

Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia.

Kratzer A, Buchebner M, Pfeifer T, Becker TM, Uray G, Miyazaki M, Miyazaki-Anzai S, Ebner B, Chandak PG, Kadam RS, Calayir E, Rathke N, Ahammer H, Radovic B, Trauner M, Hoefler G, Kompella UB, Fauler G, Levi M, Levak-Frank S, Kostner GM, Kratky D.

J Lipid Res. 2009 Feb;50(2):312-26. doi: 10.1194/jlr.M800376-JLR200. Epub 2008 Sep 23.

19.

Identification of COUP-TFII orphan nuclear receptor as a retinoic acid-activated receptor.

Kruse SW, Suino-Powell K, Zhou XE, Kretschman JE, Reynolds R, Vonrhein C, Xu Y, Wang L, Tsai SY, Tsai MJ, Xu HE.

PLoS Biol. 2008 Sep 16;6(9):e227. doi: 10.1371/journal.pbio.0060227.

20.

Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice.

Peng D, Hiipakka RA, Dai Q, Guo J, Reardon CA, Getz GS, Liao S.

J Pharmacol Exp Ther. 2008 Nov;327(2):332-42. doi: 10.1124/jpet.108.142687. Epub 2008 Aug 22.

Supplemental Content

Support Center